logo

Clementia Pharmaceuticals Inc. (CMTA)



Trade CMTA now with
  Date
  Headline
5/24/2018 10:36:58 AM Prevail Therapeutics Appoints Francois Nader To Its Board
5/23/2018 6:33:07 AM Clementia Reports Positive Phase 2 Part B Data Showing Treatment With Palovarotene
5/10/2018 8:19:55 AM Wedbush Is Lowering Clementia Pharmaceuticals Inc. (CMTA) FY18 Estimate To -1.89 From -1.57
5/10/2018 8:19:38 AM Wedbush Is Cutting Clementia Pharmaceuticals Inc. (CMTA) Q4 18 Estimate To -0.52 From -0.43
5/10/2018 8:19:19 AM Wedbush Is Cutting Clementia Pharmaceuticals Inc. (CMTA) Q3 18 Estimate To -0.49 From -0.41
5/10/2018 8:19:06 AM Wedbush Is Lowering Clementia Pharmaceuticals Inc. (CMTA) Q2 18 Estimate To -0.46 From -0.38
5/9/2018 6:39:33 AM Clementia Pharma Q1 Net Loss $13.2 Mln Or $0.42/Shr Vs Loss $41.3 Mln Or $17.48/Shr Last Year
4/20/2018 6:32:20 AM Clementia Initiates Phase 2 MO-Ped Trial For Palovarotene In Patients With Multiple Osteochondromas
3/28/2018 8:35:04 PM B. Riley FBR Initiates Clementia Pharmaceuticals Inc. (CMTA) At Buy With $25.00 Price Target
12/12/2017 6:30:59 AM Clementia Begins Pivotal Phase 3 MOVE Trial For Palovarotene In Patients With Fibrodysplasia Ossificans Progressiva
11/14/2017 2:18:14 PM Wedbush Is Cutting Clementia Pharmaceuticals Inc. (CMTA) FY18 Estimate To -1.57 From -1.48
11/14/2017 2:17:51 PM Wedbush Is Cutting Clementia Pharmaceuticals Inc. (CMTA) Q4 18 Estimate To -0.43 From -0.40
11/14/2017 2:17:33 PM Wedbush Is Cutting Clementia Pharmaceuticals Inc. (CMTA) Q3 18 Estimate To -0.41 From -0.38
11/14/2017 2:17:14 PM Wedbush Is Lowering Clementia Pharmaceuticals Inc. (CMTA) Q2 18 Estimate To -0.38 From -0.36
11/14/2017 2:16:52 PM Wedbush Is Cutting Clementia Pharmaceuticals Inc. (CMTA) Q1 18 Estimate To -0.36 From -0.34
11/14/2017 2:16:32 PM Wedbush Is Lowering Clementia Pharmaceuticals Inc. (CMTA) FY17 Estimate To -29.19 From -27.64
11/14/2017 2:16:14 PM Wedbush Is Cutting Clementia Pharmaceuticals Inc. (CMTA) Q4 17 Estimate To -0.33 From -0.31